Diabetic neuropathy. Type 2 diabetes mellitus with neurological complications
Conditions
Interventions
Intervention 1: The study intervention group includes 20 patients of both genders, aged 25 to 70 years, with diabetic neuropathy pain, who receive evening primrose soft capsules at a dose of 1000 mg e
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Having written informed consent Age 20-75 years old At least one year of type 2 diabetes Hemoglobin A1C level is smaller equal to 11% Patients should have a VAS score of 4 or more Diagnosing chronic diabetic neuropathy based on Michigan score 2 or more and ruling out other causes of neuropathy by the doctor
Exclusion criteria
Exclusion criteria: Confounding neurologic disease or neuropathy from progressive or degenerative disorders that may interfere with assessment of DPN severity. Fractures and traumatic injuries leading to sensory and motor lesions in the lower limbs uncontrolled blood pressure (systolic or diastolic blood pressure level =160 or =100 mm Hg or =95 or =60 mm Hg, respectively) leg amputation; The presence of wounds and infections in the foot heart, lung, gastrointestinal, blood, or other clinically significant endocrine disease (eg, abnormal thyroid function test even with medication). organ transplantation; AST or ALT levels more than 3 times the normal level. Serum creatinine level > 2 mg/dl. abuse of drugs or alcohol in the last year; use of an investigational drug in the last 6 months; severe or anaphylactic drug reactions;. History of allergy to medicinal plants pregnant or lactating women; Corticosteroid treatments in the last 2 months If the patients have used TCA drugs, SNRIs, gabapentinoid drugs, opioids and local treatments of capsaicin and anesthetics in the last two weeks or currently (in some patients, if possible, at the discretion of the attending physician, These drugs can be discontinued for 2 weeks and then the patient will enter the study. During these 2 weeks, acetaminophen will be used to relieve the pain of these patients). Patients treated with anticonvulsant drugs and history of seizures or schizophrenia Patients with hemophilia or other bleeding disorders and people receiving anticoagulants and warfarin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Michigan and McGill Neuropathy Questionnaire Score. Timepoint: After 4 weeks compared to the base score. Method of measurement: Michigan and McGill Neuropathy Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAyoub Gholami
Islamic Azad University
Outcome results
None listed